Scott Sommerville
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Scott Sommerville has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Ian C. Dickinson
Queensland Bone and Soft Tissue Sarcoma Service, Princess Alexandra Hospital, Brisbane, QLD, Australia; The Wesley Hospital, Brisbane, QLD, Australia
3 shared publicationsIan Dickinson
3 shared publicationsMichael Lutz
University of Queensland, School of Medicine, Herston, Brisbane, Australia
3 shared publications- Nicholas Andrew Saunders
University of Queensland, Woolloongabba, QLD, Australia
3 shared publications - Rachele Quested
University of Queensland, School of Medicine, Herston, Brisbane, Australia
3 shared publications Richard Williamson
Anatomical Pathology, MedLab Pathology, Brisbane, Queensland, Australia
3 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Taylor & Francis in Pain Management
- Vol. 16 (8) , 1-5
PET imaging of extradigital glomus tumor: a case report and literature review
1. A glomus tumor is an uncommon benign perivascular neoplasm originating from smooth muscle cells of the glomus body, an arteriovenous anastomosis surrounded by smooth muscle and neural cells that...
- 16 May 2026
- Published by Taylor & Francis in Pain Management
- Vol. 16 (8) , 1-5
Open AccessPET imaging of extradigital glomus tumor: a case report and literature review
1. A glomus tumor is an uncommon benign perivascular neoplasm originating from smooth muscle cells of the glomus body, an arteriovenous anastomosis surrounded by smooth muscle and neural cells that...
- Open Access
- 28 March 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (1)
Biomechanical analysis of ridged dorsal wrist backslabs
- 28 March 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 5 (1)
Open AccessBiomechanical analysis of ridged dorsal wrist backslabs
- Open Access
- 1 January 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (1-2) , 189-194
Unilateral hypertrophy of the tensor fascia lata muscle: a need to revisit and review
Background: Unilateral hypertrophy of the tensor fascia lata muscle is a rare phenomenon with a variety of aetiological causes. It may mimic soft tissue sarcoma, which can lead to misdiagnosis and unnecessary invasive procedures.Methods: A retrospective review was conducted of all adult patients referred to a statewide sarcoma service lata between January 2010 to June 2023 with confirmed unilateral hypertrophy of the tensor fascia. Their medical records and imaging were reviewed to identify the likely cause. All patients' histories, clinical findings and radiological investigations were reviewed by subspecialised radiologists and orthopaedic surgeons.Results: We identified nine patients with unilateral hypertrophy of the tensor fascia lata muscle. Conservative treatment was recommended to all patients, however one patient who experienced hip pain pursued surgical excision of the tensor fascia lata at another centre, with ongoing pain in the region post‐operatively.Conclusions: With ample awareness of the diagnosis and the imaging findings, this condition can be diagnosed based on history, examination and magnetic resonance imaging. Tissue biopsy and surgical excision are not indicated.
- 1 January 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (1-2) , 189-194
Open AccessUnilateral hypertrophy of the tensor fascia lata muscle: a need to revisit and review
Background: Unilateral hypertrophy of the tensor fascia lata muscle is a rare phenomenon with a variety of aetiological causes. It may mimic soft tissue sarcoma, which can lead to misdiagnosis and unnecessary invasive procedures.Methods: A retrospective review was conducted of all adult patients referred to a statewide sarcoma service lata between January 2010 to June 2023 with confirmed unilateral hypertrophy of the tensor fascia. Their medical records and imaging were reviewed to identify the likely cause. All patients' histories, clinical findings and radiological investigations were reviewed by subspecialised radiologists and orthopaedic surgeons.Results: We identified nine patients with unilateral hypertrophy of the tensor fascia lata muscle. Conservative treatment was recommended to all patients, however one patient who experienced hip pain pursued surgical excision of the tensor fascia lata at another centre, with ongoing pain in the region post‐operatively.Conclusions: With ample awareness of the diagnosis and the imaging findings, this condition can be diagnosed based on history, examination and magnetic resonance imaging. Tissue biopsy and surgical excision are not indicated.
- Open Access
- 1 April 2024
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 5 (4) , 260-268
High accuracy of positioning custom triflange acetabular components in tumour and total hip arthroplasty revision surgery
Aims: Custom triflange acetabular components (CTACs) play an important role in reconstructive orthopaedic surgery, particularly in revision total hip arthroplasty (rTHA) and pelvic tumour resection procedures. Accurate CTAC positioning is essential to successful surgical outcomes. While prior studies have explored CTAC positioning in rTHA, research focusing on tumour cases and implant flange positioning precision remains limited. Additionally, the impact of intraoperative navigation on positioning accuracy warrants further investigation. This study assesses CTAC positioning accuracy in tumour resection and rTHA cases, focusing on the differences between preoperative planning and postoperative implant positions.Methods: A multicentre observational cohort study in Australia between February 2017 and March 2021 included consecutive patients undergoing acetabular reconstruction with CTACs in rTHA (Paprosky 3A/3B defects) or tumour resection (including Enneking P2 peri-acetabular area). Of 103 eligible patients (104 hips), 34 patients (35 hips) were analyzed.Results: CTAC positioning was generally accurate, with minor deviations in cup inclination (mean 2.7°; SD 2.84°), anteversion (mean 3.6°; SD 5.04°), and rotation (mean 2.1°; SD 2.47°). Deviation of the hip centre of rotation (COR) showed a mean vector length of 5.9 mm (SD 7.24). Flange positions showed small deviations, with the ischial flange exhibiting the largest deviation (mean vector length of 7.0 mm; SD 8.65). Overall, 83% of the implants were accurately positioned, with 17% exceeding malpositioning thresholds. CTACs used in tumour resections exhibited higher positioning accuracy than rTHA cases, with significant differences in inclination (1.5° for tumour vs 3.4° for rTHA) and rotation (1.3° for tumour vs 2.4° for rTHA). The use of intraoperative navigation appeared to enhance positioning accuracy, but this did not reach statistical significance.Conclusion: This study demonstrates favourable CTAC positioning accuracy, with potential for improved accuracy through intraoperative navigation. Further research is needed to understand the implications of positioning accuracy on implant performance and long-term survival.Cite this article: Bone Jt Open 2024;5(4):260–268.
- 1 April 2024
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 5 (4) , 260-268
Open AccessHigh accuracy of positioning custom triflange acetabular components in tumour and total hip arthroplasty revision surgery
Aims: Custom triflange acetabular components (CTACs) play an important role in reconstructive orthopaedic surgery, particularly in revision total hip arthroplasty (rTHA) and pelvic tumour resection procedures. Accurate CTAC positioning is essential to successful surgical outcomes. While prior studies have explored CTAC positioning in rTHA, research focusing on tumour cases and implant flange positioning precision remains limited. Additionally, the impact of intraoperative navigation on positioning accuracy warrants further investigation. This study assesses CTAC positioning accuracy in tumour resection and rTHA cases, focusing on the differences between preoperative planning and postoperative implant positions.Methods: A multicentre observational cohort study in Australia between February 2017 and March 2021 included consecutive patients undergoing acetabular reconstruction with CTACs in rTHA (Paprosky 3A/3B defects) or tumour resection (including Enneking P2 peri-acetabular area). Of 103 eligible patients (104 hips), 34 patients (35 hips) were analyzed.Results: CTAC positioning was generally accurate, with minor deviations in cup inclination (mean 2.7°; SD 2.84°), anteversion (mean 3.6°; SD 5.04°), and rotation (mean 2.1°; SD 2.47°). Deviation of the hip centre of rotation (COR) showed a mean vector length of 5.9 mm (SD 7.24). Flange positions showed small deviations, with the ischial flange exhibiting the largest deviation (mean vector length of 7.0 mm; SD 8.65). Overall, 83% of the implants were accurately positioned, with 17% exceeding malpositioning thresholds. CTACs used in tumour resections exhibited higher positioning accuracy than rTHA cases, with significant differences in inclination (1.5° for tumour vs 3.4° for rTHA) and rotation (1.3° for tumour vs 2.4° for rTHA). The use of intraoperative navigation appeared to enhance positioning accuracy, but this did not reach statistical significance.Conclusion: This study demonstrates favourable CTAC positioning accuracy, with potential for improved accuracy through intraoperative navigation. Further research is needed to understand the implications of positioning accuracy on implant performance and long-term survival.Cite this article: Bone Jt Open 2024;5(4):260–268.
- 1 November 2020
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (11) , 2378-2380
Metastatic de-differentiated melanoma resembling synovial sarcoma diagnosed by synchronous NRAS genetic mutation
- 1 November 2020
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (11) , 2378-2380
Metastatic de-differentiated melanoma resembling synovial sarcoma diagnosed by synchronous NRAS genetic mutation
- 1 October 2020
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 29 (10) , 2104-2110
Constrained or unconstrained shoulder replacement for musculoskeletal tumor resections?
- 1 October 2020
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 29 (10) , 2104-2110
Constrained or unconstrained shoulder replacement for musculoskeletal tumor resections?
- 23 August 2019
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 18 (2) , 206-213
Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma
Osteosarcoma is the most common paediatric primary bone malignancy. The major cause of death in osteosarcoma is drug‐resistant pulmonary metastasis. Previous studies have shown that thioredoxin reductase 2 is a driver of metastasis in osteosarcoma and can be inhibited by auranofin (AF). Moreover, studies have shown that AF significantly reduces pulmonary metastases in xenotransplant models. Here, we describe a phase I/II study of AF in canine osteosarcoma, a well‐recognized spontaneous model of human osteosarcoma. We performed a single‐arm multicentre pilot study of AF in combination with standard of care (SOC) (amputation + carboplatin). We recruited 40 dogs to the trial and used a historical SOC‐only control group (n = 26). Dogs >15 kg received 9 mg AF q3d PO and dogs P= .036) in all dogs treated. The improved outcome was attributable entirely to improved OS in male dogs (P= .009). At the time of writing, 10 dogs (25%) survive without measurable disease in the treatment group with survival times ranging between 806 and 1525 days. Our study shows that AF improves OS in male dogs when combined with SOC. Our findings have translational relevance for the management of canine and human osteosarcoma. Our data justify a larger multicentre phase 2 trial in dogs and a phase I/II trial in human patients with refractory disease at the time of initial surgery.
- 23 August 2019
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 18 (2) , 206-213
Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma
Osteosarcoma is the most common paediatric primary bone malignancy. The major cause of death in osteosarcoma is drug‐resistant pulmonary metastasis. Previous studies have shown that thioredoxin reductase 2 is a driver of metastasis in osteosarcoma and can be inhibited by auranofin (AF). Moreover, studies have shown that AF significantly reduces pulmonary metastases in xenotransplant models. Here, we describe a phase I/II study of AF in canine osteosarcoma, a well‐recognized spontaneous model of human osteosarcoma. We performed a single‐arm multicentre pilot study of AF in combination with standard of care (SOC) (amputation + carboplatin). We recruited 40 dogs to the trial and used a historical SOC‐only control group (n = 26). Dogs >15 kg received 9 mg AF q3d PO and dogs P= .036) in all dogs treated. The improved outcome was attributable entirely to improved OS in male dogs (P= .009). At the time of writing, 10 dogs (25%) survive without measurable disease in the treatment group with survival times ranging between 806 and 1525 days. Our study shows that AF improves OS in male dogs when combined with SOC. Our findings have translational relevance for the management of canine and human osteosarcoma. Our data justify a larger multicentre phase 2 trial in dogs and a phase I/II trial in human patients with refractory disease at the time of initial surgery.
- Open Access
- 24 June 2019
- Published by SAGE Publications in Journal of Orthopaedics, Trauma and Rehabilitation
- Vol. 26 (1) , 14-17
The impact of preexisting disease on outcomes of simple orthopaedic trauma: A prospective cohort study
Background: This article describes a prospective cohort study trial which aims to determine what risk factors might be associated with increased levels of pain, disability and psychological distress following simple orthopaedic trauma. Methods: Patients were recruited from two large tertiary referral hospitals. Outcome measures were return to work, measurement of the visual analogue scale for pain and the SF 12 physical component score (PCS) and mental health component score. Results: Fifty-five participants were recruited. Overall, participants had significant improvement in their levels of pain, and all who were working before the injury returned to work. Those with a preexisting disease had a significantly lower ( p = 0.007) initial PCS with no significant changes in either mental health component score or PCS. Conclusions: Differences in outcomes were observed in patients with and without preexisting disease.
- 24 June 2019
- Published by SAGE Publications in Journal of Orthopaedics, Trauma and Rehabilitation
- Vol. 26 (1) , 14-17
Open AccessThe impact of preexisting disease on outcomes of simple orthopaedic trauma: A prospective cohort study
Background: This article describes a prospective cohort study trial which aims to determine what risk factors might be associated with increased levels of pain, disability and psychological distress following simple orthopaedic trauma. Methods: Patients were recruited from two large tertiary referral hospitals. Outcome measures were return to work, measurement of the visual analogue scale for pain and the SF 12 physical component score (PCS) and mental health component score. Results: Fifty-five participants were recruited. Overall, participants had significant improvement in their levels of pain, and all who were working before the injury returned to work. Those with a preexisting disease had a significantly lower ( p = 0.007) initial PCS with no significant changes in either mental health component score or PCS. Conclusions: Differences in outcomes were observed in patients with and without preexisting disease.
- 15 May 2019
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 477 (6) , 1459-1465
Is an Acetabular Cage and Cement Fixation Sufficiently Durable for the Treatment of Destructive Acetabular Metastases?
Background: Destructive bony acetabular metastases cause pain, pathological fractures, and loss of mobility. Although multiple fixation options are available, we have favored a rigid stainless steel partial pelvic cage for acetabular fixation in these patients; however, little is known about the durability of this approach. Question/purposes: (1) How common was loss of fixation in a small series of metastatic acetabular defects treated with an acetabular cage and cemented total hip replacement? (2) What is the implant survival free from reoperation or revision at 2 and 4 years using a competing-risks survivorship estimator in patients thus treated? (3) What complications were associated with the treatment? (4) What level of postoperative mobility was achieved? Methods: Between 2006 and 2017, we treated all acetabular metastases that needed surgical intervention, not amenable to conventional cemented THA alone with our single technique of acetabular partial pelvic cage and cemented total hip replacement. We treated 47 hips in 46 patients whose acetabular metastasis led to acetabular collapse or who were unresponsive to nonoperative measures of radiation therapy and analgesia. Routine followup occurred at 3 and 12 months; 17 of 46 patients (37%) died before 1 year, and all other patients were followed beyond 1 year. Only one patient who remains alive has not been seen in the past 5 years. Loss of fixation was determined by radiological or clinical signs of cage loosening. Survivorship free from reoperation or revision at 2 and 4 years was determined using competing-risks analysis. We did not assess patient-reported outcomes, but we did have data on the proportion of patients who were able to ambulate in the community and if so, what assistive devices they used, which we obtained by chart review. Results: One patient experienced cage loosening identified 8 years postoperatively as a result of local disease progression and has been managed with observation. No patients underwent revision for loss of acetabular fixation. The cumulative incidence of reoperation or revision was 8% at 2 years (95% CI, 3.6–12.6) and 16% at 4 years (95% CI, 9.2–23.2). Four patients had postoperative dislocations, of which three underwent reoperation. One patient developed a postoperative deep infection and underwent reoperation. One patient died within 30 days of surgery. Only one patient did not ambulate in the community postoperatively; 23 ambulated independently, 10 with the use of a walking stick and 12 using a walker. Conclusions: In this small series, we found this approach sufficiently durable to continue its use for patients with acetabular metastases with collapse or those not responding to nonoperative measures. However, comparison studies are needed to determine whether it is superior or inferior to other available alternatives. Level of Evidence: Level IV, therapeutic study.
- 15 May 2019
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 477 (6) , 1459-1465
Is an Acetabular Cage and Cement Fixation Sufficiently Durable for the Treatment of Destructive Acetabular Metastases?
Background: Destructive bony acetabular metastases cause pain, pathological fractures, and loss of mobility. Although multiple fixation options are available, we have favored a rigid stainless steel partial pelvic cage for acetabular fixation in these patients; however, little is known about the durability of this approach. Question/purposes: (1) How common was loss of fixation in a small series of metastatic acetabular defects treated with an acetabular cage and cemented total hip replacement? (2) What is the implant survival free from reoperation or revision at 2 and 4 years using a competing-risks survivorship estimator in patients thus treated? (3) What complications were associated with the treatment? (4) What level of postoperative mobility was achieved? Methods: Between 2006 and 2017, we treated all acetabular metastases that needed surgical intervention, not amenable to conventional cemented THA alone with our single technique of acetabular partial pelvic cage and cemented total hip replacement. We treated 47 hips in 46 patients whose acetabular metastasis led to acetabular collapse or who were unresponsive to nonoperative measures of radiation therapy and analgesia. Routine followup occurred at 3 and 12 months; 17 of 46 patients (37%) died before 1 year, and all other patients were followed beyond 1 year. Only one patient who remains alive has not been seen in the past 5 years. Loss of fixation was determined by radiological or clinical signs of cage loosening. Survivorship free from reoperation or revision at 2 and 4 years was determined using competing-risks analysis. We did not assess patient-reported outcomes, but we did have data on the proportion of patients who were able to ambulate in the community and if so, what assistive devices they used, which we obtained by chart review. Results: One patient experienced cage loosening identified 8 years postoperatively as a result of local disease progression and has been managed with observation. No patients underwent revision for loss of acetabular fixation. The cumulative incidence of reoperation or revision was 8% at 2 years (95% CI, 3.6–12.6) and 16% at 4 years (95% CI, 9.2–23.2). Four patients had postoperative dislocations, of which three underwent reoperation. One patient developed a postoperative deep infection and underwent reoperation. One patient died within 30 days of surgery. Only one patient did not ambulate in the community postoperatively; 23 ambulated independently, 10 with the use of a walking stick and 12 using a walker. Conclusions: In this small series, we found this approach sufficiently durable to continue its use for patients with acetabular metastases with collapse or those not responding to nonoperative measures. However, comparison studies are needed to determine whether it is superior or inferior to other available alternatives. Level of Evidence: Level IV, therapeutic study.
- Top Cited Papers
- 1 May 2019
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (5) , 695-702
Expanding the Spectrum of Intraosseous Rhabdomyosarcoma
Primary intraosseous rhabdomyosarcomas (RMSs) are extremely rare. Recently 2 studies reported 4 cases of primary intraosseous RMS withEWSR1/FUS-TFCP2gene fusions, associated with somewhat conflicting histologic features, ranging from spindle to epithelioid. In this study we sought to further investigate the pathologic and molecular abnormalities of a larger group of intraosseous RMSs by a combined approach using targeted RNA sequencing analysis and fluorescence in situ hybridization (FISH). We identified 7 cases, 3 males and 4 females, all in young adults, age range 20 to 39 years (median, 27 y). Three cases involved the pelvis, 2 involved the femur and 1 each involved the maxilla and the skull. Molecular studies identified recurrent gene fusions in all 7 cases tested, including: a novelMEIS1-NCOA2fusion in 2 cases,EWSR1-TFCP2in 3 cases, andFUS-TFCP2gene fusions in 1 case. One case showed aFUSgene rearrangement, without aTFCP2gene abnormality by FISH. TheMEIS1-NCOA2–positive cases were characterized by a more primitive and fascicular spindle cell appearance, while theEWSR1/FUSrearranged tumors had a hybrid spindle and epithelioid phenotype, with more abundant eosinophilic cytoplasm and mild nuclear pleomorphism. Immunohistochemically, all tumors were positive for desmin and myogenin (focal). In addition, 4 tumors withTFCP2-associated gene fusions also coexpressed ALK and cytokeratin. In conclusion, our results suggest a high incidence of gene fusions in primary RMSs of bone, with 2 molecular subsets emerging, defined by eitherMEIS1-NCOA2orEWSR1/FUS-TFCP2fusions, showing distinct morphology and immunophenotype. Additional studies with larger numbers of cases and longer follow-up data are required to definitively evaluate the biological behavior of these tumors and to establish their relationship to other spindle cell RMS genetic groups.
- 1 May 2019
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (5) , 695-702
Top Cited PapersExpanding the Spectrum of Intraosseous Rhabdomyosarcoma
Primary intraosseous rhabdomyosarcomas (RMSs) are extremely rare. Recently 2 studies reported 4 cases of primary intraosseous RMS withEWSR1/FUS-TFCP2gene fusions, associated with somewhat conflicting histologic features, ranging from spindle to epithelioid. In this study we sought to further investigate the pathologic and molecular abnormalities of a larger group of intraosseous RMSs by a combined approach using targeted RNA sequencing analysis and fluorescence in situ hybridization (FISH). We identified 7 cases, 3 males and 4 females, all in young adults, age range 20 to 39 years (median, 27 y). Three cases involved the pelvis, 2 involved the femur and 1 each involved the maxilla and the skull. Molecular studies identified recurrent gene fusions in all 7 cases tested, including: a novelMEIS1-NCOA2fusion in 2 cases,EWSR1-TFCP2in 3 cases, andFUS-TFCP2gene fusions in 1 case. One case showed aFUSgene rearrangement, without aTFCP2gene abnormality by FISH. TheMEIS1-NCOA2–positive cases were characterized by a more primitive and fascicular spindle cell appearance, while theEWSR1/FUSrearranged tumors had a hybrid spindle and epithelioid phenotype, with more abundant eosinophilic cytoplasm and mild nuclear pleomorphism. Immunohistochemically, all tumors were positive for desmin and myogenin (focal). In addition, 4 tumors withTFCP2-associated gene fusions also coexpressed ALK and cytokeratin. In conclusion, our results suggest a high incidence of gene fusions in primary RMSs of bone, with 2 molecular subsets emerging, defined by eitherMEIS1-NCOA2orEWSR1/FUS-TFCP2fusions, showing distinct morphology and immunophenotype. Additional studies with larger numbers of cases and longer follow-up data are required to definitively evaluate the biological behavior of these tumors and to establish their relationship to other spindle cell RMS genetic groups.